Importance B-cell–depleting therapies may affect the development of a protective immune
response following vaccination. Understanding the ability to develop vaccine-specific …

Importance The SARS-CoV-2 variant B. 1.1. 529 (Omicron) escapes neutralizing antibodies
elicited after COVID-19 vaccination, while T-cell responses might be better conserved. It is …

Methods| Patients from 3 university hospitals who were enrolled beginning on March 23,
2021, in an ongoing observational cohort study on immune responses after 2 doses of …

Methods| We performed a prospective observational cohort study at the Neurocenter of
Southern Switzerland. Inclusion criteria were a diagnosis of MS (using the 2017 McDonald …

Objective The purpose of this study was to investigate the effect of disease modifying
therapies on immune response to severe acute respiratory syndrome‐coronavirus 2 (SARS …

Background and Aims: The National Multiple Sclerosis Society and other expert
organizations recommended that all patients with multiple sclerosis (MS) should be …

Abstract Introduction Responses to SARS‐CoV‐2 vaccination in patients with MS (pwMS)
varies by disease‐modifying therapies (DMTs). We perform a meta‐analysis and systematic …

Background Recent observations suggest a lack of humoral response after SARS-CoV-2
vaccination in multiple sclerosis (MS) patients treated with fingolimod or ocrelizumab …

Background and objectives B-cell-depleting therapies may affect the development of a
protective immune response following vaccination against SARS-CoV-2. It is important to …

Methods| This is a prospective cohort study conducted at the MS Center Amsterdam in
Amsterdam, the Netherlands. On July 31, 2020, all adult patients with a current diagnosis of …